SCHEMBL30951504

SCHEMBL30951504

CC(C)(C)OC(=O)NS(=O)(=O)c1ccc(Br)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 7/20 0.47
NMT1 P30419 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPC1 O15118 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
USP30 Q70CQ3 1/20 0.41
ALDH1A1 P00352 1/20 0.40
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
BRS3 P32247 1/20 0.39
AKR1B1 P15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1510191 0.82 AAK1 (0.46) AAK1NPC1RAB9AALDH1A1CA12
SCHEMBL28074602 0.81 SLC1A3 (0.42) AAK1CA12CA1CA7CA14
SCHEMBL31172709 0.80 GLA (0.57) SMN1; SMN2ALDH1A1
SCHEMBL18861700 0.78 CA12 (0.41) AAK1CA12CA1CA7CA14
SCHEMBL28282423 0.78 CA12 (0.43) ALDH1A1CA12CA1CA7CA14
SCHEMBL4432604 0.78 EGFR (0.50) NPC1RECQLRAB9ASMN1; SMN2CA12
SCHEMBL31629681 0.77 CA12 (0.39) AAK1NPC1RECQLRAB9ASMN1; SMN2
SCHEMBL24757343 0.77 CA12 (0.39) AAK1NPC1RECQLRAB9ASMN1; SMN2
SCHEMBL30781615 0.77 CA12 (0.39) AAK1NPC1RECQLRAB9ASMN1; SMN2
SCHEMBL22718344 0.77 IDO1 (0.43) AAK1ALDH1A1FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630428-A1 COMPOUNDS FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-10-15 EP disclosed
WO-2024123801-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-06-13 WO disclosed